{
    "2020-09-04": [
        [
            {
                "time": "",
                "original_text": "【浙商医药|中报】创新药产业链：本土力量逐步彰显硬实力，制药升级进入兑现期",
                "features": {
                    "keywords": [
                        "创新药",
                        "产业链",
                        "本土力量",
                        "制药升级",
                        "兑现期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【浙商医药|中报总结】Q2改善，选赛道更重要",
                "features": {
                    "keywords": [
                        "Q2改善",
                        "赛道选择"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：股东贝成投资减持1.09%公司股份 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "股东减持",
                        "贝成投资"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：贝成投资累计减持436.05万股 减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "贝成投资",
                        "累计减持",
                        "436.05万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "融资客青睐8股，贝达药业买入占比高达41.09%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "融资客青睐",
                        "买入占比",
                        "41.09%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}